CORT — Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 500
- Website: https://www.corcept.com
Latest SEC filings for CORT
- SCHEDULE 13G/A — 2026-08-13
- 8-K — 2026-07-29
- 10-Q — 2026-07-29
- 8-K — 2026-06-17
- 8-K — 2026-06-03
- 8-K — 2026-05-28
- 8-K — 2026-04-30
- 10-Q — 2026-04-30
- SCHEDULE 13G/A — 2026-04-21
- SCHEDULE 13G/A — 2026-03-26
Latest CORT news
- — Corcept Therapeutics plunges 20% on Genmab cancer data (seekingalpha_market)
- — Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? (Zacks Investment Research)
- — The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics (Zacks Investment Research)
- — Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains (Zacks Investment Research)
- — 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge (Zacks Investment Research)
- — FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer (Zacks Investment Research)
- — Here's Why You Should Add EYPT Stock to Your Portfolio Now (Zacks Investment Research)
- — RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week (Zacks Investment Research)
- — LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label (Zacks Investment Research)
- — Here's Why You Should Add ANRO Stock to Your Portfolio Now (Zacks Investment Research)
Educational tool only — not investment advice.